Vorinostat
- Atc Codes:L01XX38
- CAS Codes:149647-78-9
- PHARMGKB ID:149647-78-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Zolinza; USA: Zolinza.
Drug combinations
Chemistry
Vorinostat: C~14~H~20~N~2~O~3~. Mw: 264.32. (1) Octanediamide, N-hydroxy-N’-phenyl-; (2) N-Hydroxy-N’-phenyloctanediamide. CAS-149647-78-9 (2005).
Pharmacologic Category
Other Antineoplastic Agents. Histone Deacetylase Inhibitor. (ATC-Code: L01XX38).
Mechanism of action
Inhibition of histone deacetylase enzymes, HDAC1, HDAC2, HDAC3, and HDAC6, resulting in accumulation of acetyl groups, leading to alterations in chromatin structure and transcription factor activation causing termination of cell growth leading to cell death.
Therapeutic use
Treatment of progressive, persistent, or recurrent cutaneous T-cell lymphoma.
Pregnancy and lactiation implications
Animal studies demonstrated adverse fetal effects, including fetal loss, decreased fetal weight, and skeletal malformation. There are no adequate, well-controlled studies in pregnant women. Not recommended in nursing women.
Unlabeled use
Contraindications
None known to date.
Warnings and precautions
Hazardous agent. GI toxicities (nausea, vomiting, and diarrhea) common. Dose-related anemia and thrombocytopenia may occur. May cause hyperglycemia (use with caution in diabetes mellitus). QTc prolongation observed (use caution in history of QTc prolongation or with medications known to prolong QT interval). Pulmonary embolism and deep vein thrombosis reported; monitor (use caution in history of thrombotic events).